Related Experiment Video
Updated: Jan 5, 2026
09:04
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
21.3K
Discovery of Second-Generation NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization
Journal of Medicinal Chemistry
|October 19, 2019
Summary
Researchers developed a new selective inhibitor (YQ128) for NLRP3 inflammasomes, a target for neurodegenerative diseases. While effective and brain-penetrant, YQ128 shows limited oral bioavailability, prompting further development.
Area of Science:
- Neuroscience
- Pharmacology
- Medicinal Chemistry
Background:
- NLRP3 inflammasomes are implicated in neurodegenerative disorders.
- Developing selective inhibitors is crucial for therapeutic intervention.
- Previous lead compound HL16 showed nonselective NLRP3 inhibition.
Purpose of the Study:
- To design and characterize novel selective NLRP3 inflammasome inhibitors.
- To identify a lead compound with improved potency and selectivity.
- To evaluate the brain penetration and pharmacokinetic properties of the new inhibitor.
Main Methods:
- Structure-activity relationship (SAR) studies based on HL16 scaffold.
- In vitro assays to determine IC50 values and selectivity.
- In vivo studies to assess brain penetration and pharmacokinetics in rats.
Main Results:
- A new lead compound, 17 (YQ128), was identified with an IC50 of 0.30 ± 0.01 μM.
- YQ128 demonstrated selective inhibition of NLRP3 inflammasomes.
- Compound YQ128 exhibited brain penetration and a half-life of 6.6 h in rats.
- Oral bioavailability was estimated at 10%, suggesting potential limitations.
Conclusions:
- The novel chemical scaffold yields selective NLRP3 inhibitors with brain penetration.
- YQ128 shows promise but requires pharmacokinetic optimization for oral delivery.
- Further development of analogues with enhanced oral bioavailability is warranted.
